EMA draft guideline: Multiplicity issues in clinical trials

As part of its advocacy program in Europe, ACRO submits regulatory comments to European officials. This comment letter, submitted by ACRO to EMA in 2017 about EMA draft guideline: Multiplicity issues in clinical trials can be found below.

EMA draft guideline: Multiplicity issues in clinical trials

Scroll to Top